Intravenous polyvalent immunoglobulins for autoimmune diseases in children;Traitement par immunoglobulines polyvalentes intraveineuses au cours des maladies autoimmunes de l'enfant

Presse Medicale

Volumn 27, Issue 23, 1998, Pages 1153-1158

  Karmochkine, M ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; CHILD; CHILDHOOD DISEASE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; REVIEW;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHILD; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 0032572333     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Coutinho A, Coutinho G, Grandien A, Marcos MAR, Bandeira A. Some reasons why deletion and anergy do not satisfactorily account for natural tolerance. Res Immunol 1992 ; 143:345-54.
2. Berneman A, Guilbert B, Eschrich S, Avrameas S. IgG auto-and polyreactivities of normal human sera. Mol Immunol 1993 ; 30:1499-510.
3. Coutinho A, Avrameas S, Kazatchkine MD. Natural autoantibodies. Curr Opin Immunol 1995 ; 7:812-8.
4. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci USA 1987 ; 84:828-31.
5. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992 ; 326:107-16.
6. Mouthon L, Kaveri SV, Spalter SH, Lefranc C, Desai R, Kazatchkine MD. Mechanisms of action of intravenous immunoglobulin in immune-mediated diseases. Clin Exp Immunol 1996 ; 104:3-9.
7. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to Factor VIII: C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988 ; 74:311-6.
8. Debré M, Bonnet MC, Fridman WH, et al. Infusion of Fcg fragments for the treatment of children with acute immune thrombocytopenic purpura. Lancet 1993 ; 342:945-9.
9. Basta M, Langlois PF, Marques M et al. High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1989 ; 74:326-33.
10. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994 ; 94:1729-35.
11. Andersson UG, Bjork L, Skansen-Saphir U, Andersson JP. Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology 1993 ; 79:211-6.
12. Amran A, Renz H, Lack G et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994 ; 73:180-6.
13. Aukrust P, Froland SS, Liabakk NB et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994 ; 84:2136-43.
14. van Schaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992 ; 12:325-34.
15. Kaveri SV, Vassilev T, Hurez V et al. Antibodies to a highly conserved a helix of HLA class I molecules in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996 ; 96:865-69.
16. Vassilev T, Gelin C, Kaveri SV et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use. Clin Exp Immunol 1993 ; 92:369-72.
17. Marchalonis JJ, Kaymaz H, Dedeoglu F et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor b chain. Proc Natl Acad Sci USA 1992 ; 89:3325-9.
18. Dietrich G, Varela F, Hurez V, Bouanami M, Kazatchkine MD. Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol 1993 ; 21:2945-50.
19. Kazatchkine MD, Dietrich G, Hurez V et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 1994 ; 139:79-107.
20. Sullivan KM, Kopecky KG, Jocom J et al. Immunomodulatory and anti-microbial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990 ; 323:705-9.
21. Minvielle E, Viens-Bitker C, Rochant H et al. La maîtrise de la diffusion d'une innovation en Santé : le cas des immunoglobulines intraveineuses polyvalentes à l'Assistance Publique-Hôpitaux de Paris. Ann Med Interne 1995 ; 146:19-24.
22. American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997 ; 126:319-26.
23. Medeiros D, Buchanan GR. Current controversies in the management of idiopathic thrombocytopenic purpura during childhood. Pediatr Clin North Am 1996 ; 43:757-72.
24. Hord JD, Grossman NJ. Intravenous corticosteroids versus intravenous gammaglobulin in the treatment of acute immune thrombocytopenic purpura. Pediatr Hematol Oncol 1993 ; 10:323-7.
25. Blanchette V, Imbach P, Andrew M et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994 ; 344:703-7.
26. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 ; 88:3-40.
27. Warrier I, Bussel JB, Valdez L et al. Safety and efficacy of low-dose intravenous immune globulin (IVIg) treatment for infants and children with immune thrombocytopenic purpura. J Pediatr Hemat Oncol 1997 ; 19:197-201.
28. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor and gamma interferon in Kawasaki disease involved coronary-artery lesion. Clin Immunol Immunopothol 1990 ; 56:29-36.
29. Furukawa S, Matsubara T, Yabuta K. Mononuclear cell subsets and coronary artery lesions in Kawasaki disease. Arch Dis Child 1992 ; 67:706-8.
30. Leung DYN, Kurt-Jones E, Newburger J et al. Endothelial cell activation of high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989 ; ii: 1298-302.
31. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki diseases meta-analysis on the efficacy of aspirin and immunoglobulin treatment Pediatrics 1995 ; 96:1057-61.
32. Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis:a phase I/II study. J Rheumatol 1996 ; 25:919-24.
33. Roifman CM. Use of intravenous immune globulin in the therapy of children with rheumatological diseases. J Clin Immunol 1995 ; 15(Suppl 6):42S-51S.
34. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four year review of nine cases. Arch Dis Child 1995 ; 72:25-8.
35. Dalakas MC, Illa I, Dambrosia JM et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. W Engl J Med 1993 ; 329:1993-2000.
36. van der Meché FGA, Schmitz PIM, and the Dutch Guillain-Barré study group. A randomiezd trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992 ; 326:1123-9.
37. Vallée L, Dulac O, Nuyts JP, Leclerc F, Vamecq J. Intravenous immune globulin is also efficient therapy of acute Guillain-Barré syndrome in affected children. Neuropediatrics 1993 ; 24:235-6.
38. Gurses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995 ; 27:241-3.
39. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993 ; 44:237-42.
40. Drucker NA, Colan SD, Lewis AB et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994 ; 89:252-7.
41. Rowe PC, Mc Lean RH, Ruley EJ. Intravenous immunoglobulin in minimal change nephrotic syndrome: cross-over trial. Pediatr Nephrol 1990 ; 4:32-5.
42. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic disease. Clin Exp Immunol 1996 ; 104:61-66.
43. Jakobsson T, Croner S, Kjellman NIM, Pattersson A, Vassella C, Björksten B. Slight steroid-sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma. Allergy 1994 ; 49:413-20.
44. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994 ; 331:1649-50.
45. Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996 ; 104(Suppl 1):35-42.
46. Bjoro K, Froland SS, Yun ZB; Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994 ; 331:1607-11.
47. Morgenthaler JJ. Methods for inactivation of viruses in plasma products. In: Biotechnology of blood proteins, Rival C et Stoltz JF (eds). Editions INSERM, Montrouge, 1993 ; 227:221-8.
48. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy:frequency and risk factors. Ann Intern Med 1994 ; 121:259-62.
49. Cantu TG, Hoehn-Saric E, Burgess KM, Racusen L, Scheel PJ. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995 ; 25:228-34.